Hironori Fukuda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hironori Fukuda has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Kazunori Aoki
Department of Immune Medicine, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan
99 shared publications - Makiko Yamashita
The Cancer Institute Hospital of JFCR 4 Koto-ku, Tokyo
98 shared publications - Shigehisa Kitano
Division of Cancer Immunotherapy Development, Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
98 shared publications - Nobuyoshi Hiraoka
Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
71 shared publications - Teruhiko Yoshida
Department of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan
71 shared publications - Yasuhito Arai
Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan
71 shared publications
Latest Publications
- 12 October 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (10) , e70670
Factors Associated With Trifecta and Pentafecta Achievement in Robot‐Assisted Laparoscopic Partial Nephrectomy for Highly Complex Renal Tumors
Background: Robot‐assisted laparoscopic partial nephrectomy (RAPN) for highly complex renal tumors can be challenging. However, determinants of oncological and functional outcomes after RAPN in this high‐risk population remain poorly characterized. Methods: We retrospectively evaluated the clinical data of 396 consecutive patients who underwent RAPN for cT1N0M0 renal tumors of high complexity, defined as a RENAL nephrectomy score ≥ 10. Factors associated with trifecta (negative surgical margin, warm ischemic time ≤ 25 min, and no surgical complications) and pentafecta achievement (≥ 90% estimated glomerular filtration rate preservation and no chronic kidney disease stage upgrade at 1 year postoperatively, along with trifecta achievement) were investigated. Results: Trifecta was achieved in 201 patients (51%). Multivariable analysis showed that right‐side tumors ( p = 0.0217), non‐hilar tumors ( p = 0.0056), shorter operating times ( p < 0.0001), and unexposed urinary systems ( p = 0.0022) were independent factors for trifecta achievement. Among 334 patients with eligible data for pentafecta evaluation, 104 (31%) achieved pentafecta. After covariate adjustment, non‐hilar tumors ( p = 0.0449), shorter operating times ( p = 0.0003), and unexposed urinary systems ( p = 0.0004) were independent factors for pentafecta achievement. Conclusion: Factors associated with trifecta and pentafecta achievement after RAPN were identified for highly complex renal tumors. These perioperative factors may be utilized for postoperative outcome prediction after RAPN in this challenging population.
- 12 October 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (10) , e70670
Factors Associated With Trifecta and Pentafecta Achievement in Robot‐Assisted Laparoscopic Partial Nephrectomy for Highly Complex Renal Tumors
Background: Robot‐assisted laparoscopic partial nephrectomy (RAPN) for highly complex renal tumors can be challenging. However, determinants of oncological and functional outcomes after RAPN in this high‐risk population remain poorly characterized. Methods: We retrospectively evaluated the clinical data of 396 consecutive patients who underwent RAPN for cT1N0M0 renal tumors of high complexity, defined as a RENAL nephrectomy score ≥ 10. Factors associated with trifecta (negative surgical margin, warm ischemic time ≤ 25 min, and no surgical complications) and pentafecta achievement (≥ 90% estimated glomerular filtration rate preservation and no chronic kidney disease stage upgrade at 1 year postoperatively, along with trifecta achievement) were investigated. Results: Trifecta was achieved in 201 patients (51%). Multivariable analysis showed that right‐side tumors ( p = 0.0217), non‐hilar tumors ( p = 0.0056), shorter operating times ( p < 0.0001), and unexposed urinary systems ( p = 0.0022) were independent factors for trifecta achievement. Among 334 patients with eligible data for pentafecta evaluation, 104 (31%) achieved pentafecta. After covariate adjustment, non‐hilar tumors ( p = 0.0449), shorter operating times ( p = 0.0003), and unexposed urinary systems ( p = 0.0004) were independent factors for pentafecta achievement. Conclusion: Factors associated with trifecta and pentafecta achievement after RAPN were identified for highly complex renal tumors. These perioperative factors may be utilized for postoperative outcome prediction after RAPN in this challenging population.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors
Supplementary Table 4. Univariable and multivariate analyses for PFS and OS
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors
Supplementary Table 4. Univariable and multivariate analyses for PFS and OS
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Table S14 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors
Supplementary Table 14. Comparison of expression levels of specific immune-related genes stratified by histopathology
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S14 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors
Supplementary Table 14. Comparison of expression levels of specific immune-related genes stratified by histopathology
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Table S16 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors
Supplementary Table 16. Characteristics of patients whose tumor samples were used for flow cytometry stratified by histopathology
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S16 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors
Supplementary Table 16. Characteristics of patients whose tumor samples were used for flow cytometry stratified by histopathology
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors
Supplementary Figure 5. Prognostic impact of TIME phenotype in ICI combination therapy
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors
Supplementary Figure 5. Prognostic impact of TIME phenotype in ICI combination therapy
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors
Supplementary Table 6. Patient characteristics of the IO-TKI treatment group
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors
Supplementary Table 6. Patient characteristics of the IO-TKI treatment group
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Table S13 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors
Supplementary Table 13. Sample list
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S13 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors
Supplementary Table 13. Sample list
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Table S8 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors
Supplementary Table 8. Tumor responses in the IO-TKI treatment group
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors
Supplementary Table 8. Tumor responses in the IO-TKI treatment group
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors
Supplementary Table 2. Histopathological profiles of non-clear-cell renal cell carcinoma
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors
Supplementary Table 2. Histopathological profiles of non-clear-cell renal cell carcinoma
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Table S17 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors
Supplementary Table 17. Comparison of the number of tumor-infiltrating immune cells stratified by histopathology
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S17 from Non–Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors
Supplementary Table 17. Comparison of the number of tumor-infiltrating immune cells stratified by histopathology